BIOCON - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.6
| Stock Code | BIOCON | Market Cap | 59,763 Cr. | Current Price | 369 ₹ | High / Low | 425 ₹ |
| Stock P/E | 745 | Book Value | 120 ₹ | Dividend Yield | 0.14 % | ROCE | 2.09 % |
| ROE | 0.40 % | Face Value | 5.00 ₹ | DMA 50 | 379 ₹ | DMA 200 | 369 ₹ |
| Chg in FII Hold | 0.53 % | Chg in DII Hold | 2.07 % | PAT Qtr | 70.9 Cr. | PAT Prev Qtr | -8.30 Cr. |
| RSI | 43.1 | MACD | -4.67 | Volume | 19,32,501 | Avg Vol 1Wk | 39,01,623 |
| Low price | 291 ₹ | High price | 425 ₹ | PEG Ratio | -40.0 | Debt to equity | 0.16 |
| 52w Index | 58.0 % | Qtr Profit Var | 2,116 % | EPS | 5.51 ₹ | Industry PE | 29.1 |
📊 Analysis: BIOCON is trading at ₹369, right at its 200 DMA (₹369) but below the 50 DMA (₹379), showing weak momentum. RSI at 43.1 indicates neutral-to-weak strength, while MACD at −4.67 confirms bearish divergence. Current volume (19,32,501) is significantly lower than the weekly average (39,01,623), suggesting limited intraday participation. The extremely high P/E of 745 compared to industry average (29.1) highlights stretched valuations, making intraday trades risky despite recent profit recovery.
💡 Optimal Buy Price: ₹365–368 if support holds intraday.
🎯 Profit-Taking Levels: ₹378–382 (short-term resistance).
🛡️ Stop-Loss: ₹360 (below near-term support).
⏱️ Exit Strategy if Already Holding: Consider booking profits near ₹378–382 if momentum slows. If price breaks below ₹365 with rising volume, exit intraday to protect capital.
✅ Positive
- Quarterly PAT improved sharply from a loss (−₹8.3 Cr.) to ₹70.9 Cr.
- DII holding increased (+2.07%), showing strong domestic institutional support.
- FII holding also increased (+0.53%), reflecting foreign investor confidence.
- 52-week index gain of 58% highlights long-term investor interest.
⚠️ Limitation
- Extremely high P/E (745) compared to industry average (29.1), making valuation unsustainable.
- Weak ROCE (2.09%) and ROE (0.40%) reflect poor capital efficiency.
- MACD negative, indicating short-term weakness in momentum.
- Volume below weekly average, reducing intraday trading opportunities.
📉 Company Negative News
- EPS remains low at ₹5.51 despite large market cap.
- Dividend yield at only 0.14%, offering minimal shareholder returns.
📈 Company Positive News
- Quarterly profit turnaround (+2,116% variation) signals operational recovery.
- Institutional support from both FII and DII holdings increased.
🏭 Industry
- Biopharma sector trades at Industry PE of 29.1, far lower than BIOCON’s valuation.
- Sector growth supported by rising demand for generics and biosimilars globally.
🔎 Conclusion
BIOCON is a weak candidate for intraday trading today due to bearish technicals, low volume, and unsustainable valuation. While the profit turnaround and institutional support are positives, traders should exercise caution. Conservative trades may be attempted near ₹365–368 with tight stop-losses, but risk remains elevated. Better suited for medium-term recovery plays rather than intraday scalping.